A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

PURPOSE: To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. METHODS: This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m(2) given on Day 1 of each...

Descripción completa

Detalles Bibliográficos
Autores principales: Resta, Lee P., Pili, Roberto, Eisenberger, Mario A., Spitz, Avery, King, Serina, Porter, Jennifer, Franke, Amy, Boinpally, Ramesh, Carducci, Michael A., Sweeney, Christopher J.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028086/
https://www.ncbi.nlm.nih.gov/pubmed/20445979
http://dx.doi.org/10.1007/s00280-010-1328-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028086/
https://www.ncbi.nlm.nih.gov/pubmed/20445979
http://dx.doi.org/10.1007/s00280-010-1328-7

Ejemplares similares